- Home
- NMCO vs CRMD Comparison
NMCO vs CRMD Comparison
Compare NMCO & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMCO
- CRMD
- Stock Information
- Founded
- NMCO 2019
- CRMD 2006
- Country
- NMCO United States
- CRMD United States
- Employees
- NMCO N/A
- CRMD N/A
- Industry
- NMCO Finance/Investors Services
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- NMCO Finance
- CRMD Health Care
- Exchange
- NMCO Nasdaq
- CRMD Nasdaq
- Market Cap
- NMCO 594.1M
- CRMD 925.6M
- IPO Year
- NMCO N/A
- CRMD 2010
- Fundamental
- Price
- NMCO $10.90
- CRMD $12.65
- Analyst Decision
- NMCO
- CRMD Strong Buy
- Analyst Count
- NMCO 0
- CRMD 8
- Target Price
- NMCO N/A
- CRMD $17.57
- AVG Volume (30 Days)
- NMCO 207.6K
- CRMD 4.5M
- Earning Date
- NMCO 01-01-0001
- CRMD 10-29-2025
- Dividend Yield
- NMCO 5.43%
- CRMD N/A
- EPS Growth
- NMCO N/A
- CRMD N/A
- EPS
- NMCO N/A
- CRMD 0.79
- Revenue
- NMCO N/A
- CRMD $121,484,498.00
- Revenue This Year
- NMCO N/A
- CRMD $404.81
- Revenue Next Year
- NMCO N/A
- CRMD $56.11
- P/E Ratio
- NMCO N/A
- CRMD $15.97
- Revenue Growth
- NMCO N/A
- CRMD 14970.29
- 52 Week Low
- NMCO $8.52
- CRMD $5.60
- 52 Week High
- NMCO $11.64
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- NMCO 80.72
- CRMD 46.65
- Support Level
- NMCO $10.26
- CRMD $12.73
- Resistance Level
- NMCO $10.40
- CRMD $13.83
- Average True Range (ATR)
- NMCO 0.09
- CRMD 0.76
- MACD
- NMCO 0.06
- CRMD -0.17
- Stochastic Oscillator
- NMCO 100.00
- CRMD 31.66
About NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.